Skip to main content
Caplight Logo









Oculogenex

Oculogenex

Private
La Habra, CaliforniaHealthcare & Life Scienceshttps://oculogenex.com/

Last Round

Grant

May 1, 2022

Total Funding Raised

$1.28M

Company Overview

Oculogenex is a biotechnology company developing a regenerative gene therapy to treat retinal disorders such as dry age-related macular degeneration.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Space Technology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyage-related macular degenerationAMDretinal diseaseAAVadeno-associated viral vectorsregenerative medicinegeographic atrophybiotech startupocular therapyspace-based researchdrug discoveryretinal stem cellsprecision medicineeye health tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oculogenex Comparables

Compare Oculogenex with similar companies based on industry and business-model similarity.

Oculogenex comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Perceive Biotherapeutics, Inc.
84%
Complement Therapeutics GmbH
82%
Beacon Therapeutics
81%

Oculogenex Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 1, 2022
GrantOct 28, 2021
GrantMay 1, 2021
GrantFeb 6, 2021

Key People

Founding team and executive leadership

FASRS Hema Ramkumar

Chief Executive Officer

Executive Team

Ram Ramkumar

Chief Operating Officer

Executive Team

Oculogenex Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2022

    Received $1M grant from the National Science Foundation.

  • Nov 2, 2021

    Received grant funding from Boeing and MassChallenge.

Oculogenex Filings

Explore SEC and related filing metadata, where available.

Oculogenex filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Oculogenex's valuation, stock price, and market status.

Is Oculogenex a public or private company?

Oculogenex is a private company.

What is the current stock price of Oculogenex?

Oculogenex is a private company with no public stock price. No recent secondary market data is available.

How much is Oculogenex worth (valuation)?

Valuation information for Oculogenex is not publicly available.

Can I buy Oculogenex stock?

Oculogenex shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Oculogenex's last funding round?

Oculogenex's most recent funding round was Grant on May 1, 2022.

Who are the main investors in Oculogenex?

Key investors in Oculogenex include The Winning Pitch Challenge, National Science Foundation.

Will Oculogenex IPO soon?

No public IPO plans have been announced for Oculogenex.

How can I track Oculogenex secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Oculogenex's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLa Habra, California
Employee Range3
Year Founded2020
Last FundingMay 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?